Q4 2019 13F Holders as of 31 Dec 2019
-
Type / Class
-
Equity / COM
-
Number of holders
-
46
-
Total 13F shares, excl. options
-
17,486,780
-
Shares change
-
-2,249,124
-
Total reported value, excl. options
-
$22,557,204
-
Value change
-
-$2,351,721
-
Put/Call ratio
-
12%
-
Number of buys
-
19
-
Number of sells
-
-34
-
Price
-
$1.29
Significant Holders of BELLICUM PHARMACEUTICALS INC - COM (BLCM) as of Q4 2019
68 filings reported holding BLCM - BELLICUM PHARMACEUTICALS INC - COM as of Q4 2019.
BELLICUM PHARMACEUTICALS INC - COM (BLCM) has 46 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 17,486,780 shares
.
Largest 10 shareholders include BAKER BROS. ADVISORS LP (2,677,818 shares), RENAISSANCE TECHNOLOGIES LLC (2,583,840 shares), Sumitomo Mitsui Trust Holdings, Inc. (2,300,682 shares), Nikko Asset Management Americas, Inc. (2,300,682 shares), VANGUARD GROUP INC (1,778,926 shares), FRAZIER MANAGEMENT LLC (1,051,441 shares), BlackRock Inc. (1,007,837 shares), PRINCIPAL FINANCIAL GROUP INC (503,151 shares), ARK Investment Management LLC (417,433 shares), and GEODE CAPITAL MANAGEMENT, LLC (416,449 shares).
This table shows the top 46 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.